We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BIOMARKERS COULD SAVE FIRMS MILLIONS IN R&D COSTS ON CLINICAL TRIALS
BIOMARKERS COULD SAVE FIRMS MILLIONS IN R&D COSTS ON CLINICAL TRIALS
November 5, 2004
Drugmakers could reduce the size of their clinical trials and save millions of dollars in development costs by using predictive biomarkers for distinguishing promising drug candidates from likely failures, according to the FDA’s acting commissioner.